


Biochemical Characterization of Selective Inhibitors of Human Group IIA Secreted Phospholipase A2 and Hyaluronic Acid-Linked Inhibitor **Conjugates**

Rob C. Oslund[†] and Michael H. Gelb*,[†],[‡]

[†]Departments of Chemistry and Biomolecular Structure and Design and [‡]Department of Biochemistry, University of Washington, Seattle, Washington 98195, United States

Supporting Information

ABSTRACT: We explored the inhibition mode of group IIA secreted phospholipase A2 (GIIA sPLA2) selective inhibitors and tested their ability to inhibit GIIA sPLA₂ activity as chemical conjugates with hyaluronic acid (HA). Analogues of a benzo-fused indole sPLA2 inhibitor were developed in which the carboxylate group on the inhibitor scaffold, which has been shown to coordinate to a Ca²⁺ ligand in the enzyme active site, was replaced with other functionality. Replacing the carboxylate group with amine, amide, or hydroxyl groups had no effect on human GIIA (hGIIA) sPLA2 inhibition potency but dramatically lowered inhibition potency against hGV and hGX sPLA2s. An alkylation protection assay was used to probe active site binding of carboxylate and



noncarboxylate inhibitors in the presence and absence of Ca2+ and/or lipid vesicles. We observed that carboxylate-containing inhibitors bind the hGIIA sPLA2 active site with low nanomolar affinity, but only when Ca2+ is present. Noncarboxylate, GIIA sPLA₂ selective inhibitors also bind the hGIIA sPLA₂ active site in the nanomolar range. However, binding for GIIA sPLA₂ selective inhibitors was dependent on the presence of a lipid membrane and not Ca²⁺. These results indicate that GIIA sPLA₂ selective inhibitors exert their inhibitory effects by binding to the hGIIA sPLA2 active site. An HA-linked GIIA inhibitor conjugate was developed using peptide coupling conditions and found to be less potent and selective against hGIIA sPLA2 than the unconjugated inhibitor. Compounds reported in this study are some of the most potent and selective GIIA sPLA2 active site binding inhibitors reported to date.

S ecreted phospholipases A_2 (sPLA2s) make up a family of Ca^{2+} -dependent, disulfide-rich enzymes that catalyze the hydrolysis of glycerophospholipids at the sn-2 position to liberate lysophospholipid and fatty acid products. Ten sPLA₂s have been identified in mammals (groups IB, IIA, IIC, IID, IIE, IIF, III, V, X, and XIIA), and in humans, all of these enzymes are present except the group IIC enzyme, which exists as a pseudogene.^{2,3} The lipolytic activity of these enzymes has important implications in inflammation because hydrolysis products such as arachidonic acid (AA) can be further processed into important proinflammatory mediating eicosanoids such as prostaglandins and leukotrienes.^{1,3} In fact, sPLA₂ activity has been connected to a number of inflammatory diseases, including atherosclerosis, asthma, and arthritis. 1,3 Not surprisingly, this has led to greater efforts to develop small molecule inhibitors that target sPLA₂s.^{4,5}

Some of the earliest evidence of a proinflammatory function of sPLA2s came more than two decades ago with the discovery of large amounts of human GIIA (hGIIA) sPLA2 in rheumatoid arthritic and osteoarthritic synovial fluid.^{6,7} The discovery of increased levels of GIIA sPLA2 in arthritic synovial fluid has raised the possibility that this and other sPLA2 enzymes may be involved in the development of arthritis through generation of eicosanoids and that inhibition of sPLA2 activity may alleviate joint inflammation. Current evidence suggests that treatment of

arthritis through sPLA2 inhibition may require selective targeting of GIIA over other sPLA2s.8 Using a mouse arthritis model, the Lee lab showed that GIIA and GV sPLA2s play opposing roles in arthritis disease progression where the GIIA enzyme contributes to arthritis development but GV plays an anti-inflammatory role.8 This is among the first evidence showing that sPLA2s can perform opposing roles in an inflammatory disease, and it may explain why earlier attempts to treat rheumatoid arthritis with an sPLA2 indole-based inhibitor that potently inhibits both GIIA and GV failed to show efficacy. Furthermore, this suggests an important need for developing GIIA sPLA2 selective inhibitors that can target the proinflammatory functions of GIIA, but not the protective functions of GV in arthritis development.

We recently reported on the development of an indole-based inhibitor that was selective for GIIA over GV and other ${
m sPLA}_2{
m s.}^{10}$ In this study, we showed that compound 1 (Figure 1A) was a generally potent sPLA2 inhibitor with nanomolar inhibition potency against all sPLA2s except GIII and GXIIA. 10 A key binding feature of compound 1 is the carboxylate group that has been shown, using a similar structural analogue, to

Received: August 23, 2012 Revised: September 26, 2012 Published: September 28, 2012




Figure 1. (A) Structures of the generally potent (1) and GIIA selective (2a) sPLA₂ inhibitors. (B) Crystal structure highlighting the key binding interactions between the structurally related inhibitor, Me-Indoxam, and the hGX active site.

contact a calcium ion in the enzyme active site (Figure 1B).¹¹ However, removal of this Ca²⁺-binding, carboxylate moiety on compound 1 to give 2a (Figure 1A) severely diminished inhibition potency against most sPLA₂s but had no effect on human and mouse GIIA sPLA₂ inhibition potency.¹⁰ From these studies, it was unclear whether the GIIA sPLA₂ inhibition caused by 2a still required calcium and/or whether the inhibitory effects were due to active site or allosteric site binding. Given the recent interest in developing GIIA sPLA₂ selective inhibitors as described above, we performed further studies investigating the mode of GIIA sPLA₂ inhibition for this compound.

We first investigated the range of functional groups that could replace the 4-position carboxylate on compound 1 without disrupting hGIIA sPLA2 inhibition potency and selectivity. We then explored the ability of GIIA sPLA, selective compounds to bind the enzyme active site using an alkylation protection assay that specifically probes active site binding. These active site studies were conducted in the presence and absence of Ca²⁺ and/or a membrane to test the importance of these two factors on inhibitor binding. Because the carboxylate group of indole-based compounds does not appear to be important for GIIA sPLA2 inhibition selectivity, we investigated the novel use of GIIA sPLA2 selective inhibitors as chemical conjugates with hyaluronic acid (HA) for the potential treatment of osteoarthritis (OA). Intra-articular injection of HA is a current treatment option that can provide symptomatic relief from OA by temporarily restoring viscoelasticity and other normal properties to the diseased joint. 12,13 We reasoned that HA conjugated with a GIIA sPLA $_2$ selective inhibitor could combine the anti-inflammatory properties of GIIA sPLA2 inhibition with the lubrication and viscosupplementation features provided by the HA polymer. As a proof of principle, we also set out to synthesize HA-inhibitor conjugates and then test their ability to inhibit hGIIA sPLA2 activity in vitro.

MATERIALS AND METHODS

Materials. hGIIA sPLA₂ was prepared and purified as described previously, ¹⁴ and hGV and hGX sPLA₂s were prepared and purified as described previously. ¹⁵ DMPM was from Alexis Corp. DTPM was synthesized as described previously, ¹⁶ and pyrPG was purchased from Molecular Probes or prepared as described in the Supporting Information. Compounds **1**, **2a**, and **3a** were synthesized as described previously. ¹⁰ Phenacyl bromide was from Sigma, fatty acid free bovine serum albumin (BSA) was from Sigma (catalog no. A6003), 20 kDa HA was from Lifecore Biomedical, hydroxybenzotriazole (HOBt) was from Pierce, and 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC) was from TCI America. Purified water was from a Milli-Q system (Millipore Corp., Billerica, MA).

Synthesis of sPLA₂ Inhibitors. Inhibitors were prepared as described in the Supporting Information.

Determination of IC_{50} Values. IC_{50} values were obtained from each of the enzyme assays reported below using five inhibitor concentrations ranging from 10 to 90% inhibition of $sPLA_2$ activity. IC_{50} values were determined by nonlinear regression analysis of a semilog plot of percent inhibition versus the log of inhibitor concentration. The inhibition curves were generated using Kaleidagraph.

Fluorometric Enzyme Assay. This assay was performed as previously described. ^{17,18}

Radiometric Enzyme Assay. This assay was performed as previously described. ¹⁰ hGIIA was used at 15 pg/reaction.

pH-Stat Titration Enzyme Assay. This assay has been described previously¹⁹ but was slightly modified for our inhibition studies. hGIIA sPLA2 activity was monitored by continuous titration of the hydrolyzed fatty acid at a constant pH (8.0) in a pH-stat instrument (Radiometer, Copenhagen, Denmark). The pH-stat consisted of a pH meter (PHM 82), a titrator (TTT 80), an autoburet (ABU 80), a thermostatcontrolled titration assembly unit (TTA 80), and a pH electrode (Radiometer Analytical, PHC 4006-9). All assays were conducted at room temperature under N₂. Five milliliters of an assay solution (1 mM NaCl and 0.6 mM CaCl₂) was placed into the reaction vessel, and the pH was adjusted to 8.0 using an autoburet with 2.8 mM NaOH as the titrant. Once the baseline had stabilized with zero drift, 62 µL of DMPM vesicles from a 16 mM stock solution in purified water was added to the reaction vessel to give a final concentration of 200 µM. The preparation of DMPM vesicles was conducted exactly as described previously. 19 The pH of the mixture was adjusted to 8.0 with the autoburet, and the baseline was allowed to stabilize over 3-5 min. hGIIA sPLA₂ in 5 μ L of purified water was added to the reaction mixture to give a final concentration of 14 nM, and the enzyme activity was monitored by autotitration using 2.8 mM NaOH at a maintained pH of 8.0. Under these conditions, we generally observed a linear initial velocity (v_0) over the first 6-8 min of the reaction progress curve. For inhibitor studies, the enzyme was first added to the reaction vessel, and the v_0 was measured over the first 2-3 min. Inhibitor in 2 μ L of DMSO was then added, and the reaction velocity in the presence of inhibitor (v_i) was measured over 2– 3 min. The percent inhibition was calculated as $100 - [(v_i/v_o)]$ \times 100].

Alkylation Protection Studies. Inactivation of hGIIA sPLA₂ activity in the presence of phenacyl bromide was conducted as reported previously but with a few modifica-

tions.²⁰ Binding assay buffer (200 µL) consisting of 50 mM sodium cacodylate (pH 7.3), 50 mM NaCl, 0.1% BSA, and either 200 μ M CaCl₂ or 100 μ M EGTA was added to a 600 μ L microcentrifuge tube (Neptune Plastics). Inhibitor (1 μ L in DMSO) or DMSO vehicle control was added to the reaction mixture. hGIIA sPLA₂ in 1 μ L of 10 mM Tris (pH 8.0) was then added to the reaction mixture to give a final concentration of 250 nM and briefly vortexed. For inactivation studies involving the membrane, 2.5 µL of DTPM vesicles from a 17 mM stock solution in purified water was added to the assay buffer at 200 μ M prior to the addition of the inhibitor. DTPM vesicles were prepared following the exact procedure outlined for the preparation of DMPM vesicles. 19 Phenacyl bromide was dissolved in acetonitrile at a concentration of 350 mM and added to the assay mixture at a concentration of 3.5 mM to start the assay. Aliquots (2 μ L) of the assay mixture were removed at appropriate time points and diluted 400-fold in solution A consisting of 50 mM Tris (pH 8.0), 50 mM KCl, 100 μ M EGTA, and 0.1% BSA; 50–100 μ L of the diluted assay mixture was then added to a well of a 96-well microtiter plate and diluted to 200 μ L with solution A. This was followed by addition of 100 μ L of solution B consisting of 4.2 μ M pyrPG in 50 mM KCl, 100 μ M EGTA, and 50 mM Tris-HCl (pH 8.0). Enzyme activity was initiated by addition of 20 μ L of 50 mM CaCl₂. The initial velocity of pyrPG hydrolysis was monitored over 2-3 min by measuring the increase in pyrene monomer fluorescence (excitation at 342 nm and emission at 395 nm) with a Victor3V microtiter plate spectrophotometer (Perkin-Elmer). In all alkylation assays, the first time point was taken seconds after the addition of phenacyl bromide (t = 0 min)followed by three other time points taken over the course of the inactivation assay until ≈10% of enzyme activity remained. The percent enzyme activity over the course of the reaction was determined by dividing the initial velocity of enzyme activity at a given time point by the initial velocity of enzyme activity at time zero. Semilog plots of log(% activity) versus time gave a straight line from which the inactivation half-times were determined.

Values of K_d were calculated from a modified form of the Scrutton and Utter equation (eq 1):

$$\frac{1}{1 - t_{\rm o}/t_{\rm i}} = \frac{K_{\rm d}/[{\rm I}] + 1}{1 - k_{\rm i}/k_{\rm o}} \tag{1}$$

where $t_{\rm o}$ and $t_{\rm i}$ are the respective inactivation half-times in the absence and presence of inhibitor, respectively, [I] is the inhibitor concentration, and $k_{\rm i}$ and $k_{\rm o}$ are the inactivation rate constants in the presence of a saturating inhibitor concentration and absence of inhibitor, respectively. Note that [I] is used in place of $X_{\rm L}$ from the original equation because we do not accurately know the mole fraction of inhibitor that partitions onto the lipid surface when the membrane is used in the assay. A plot of $1/(1-t_{\rm o}/t_{\rm i})$ versus $1/[{\rm I}]$ yields a straight line in which the x-intercept equals $-1/K_{\rm d}$. Scrutton and Utter plots were generated from five different inhibitor concentrations, and the $K_{\rm d}$ value was determined from the x-intercept.

Synthesis of HA–Inhibitor Conjugates. Hyaluronic acid (20 kDa) (5 mg, 0.012 mmol) was dissolved in 1.25 mL of a 1:1 mixture of THF and 0.1 M 2-(N-morpholino)-ethanesulfonic acid (MES) (pH 5.1). Free amine compound 4d or 4d-Nme (2.5 mg, 0.006 mmol) was dissolved in 1 mL of a 1:1 THF/0.1 M MES mixture (pH 5.1) and added to the reaction mixture, and it was stirred for 2–3 min (see the

Supporting Information for preparation of free amine 4d or 4d-Nme). HOBt (3.6 mg, 0.024 mmol) was added to the reaction mixture, and it was stirred until the HOBt was completely dissolved. EDC (35 mg, 0.18 mmol) was dissolved in 250 μ L of a 1:1 THF/0.1 M MES mixture (pH 5.1) and added dropwise to the reaction mixture while being stirred constantly. The reaction mixture was then stirred for 2 h at room temperature. Purified water (1.25 mL) was then added to the reaction mixture, and the sample was placed in a Speed-Vac to remove the THF (≈1.25 mL). The remaining reaction mixture was diluted to a final volume of 2.5 mL with purified water and loaded onto a PD-10 disposable size exclusion column (bed volume, 8.3 mL) (GE Healthcare) that was pre-equilibrated with 100 mM NaCl and then eluted off the column with 3.5 mL of 100 mM NaCl. The eluted product was concentrated to a final volume of 2.5 mL in a Speed-Vac. This reaction mixture was loaded onto a second PD-10 column (equilibrated with purified water) and eluted off the column with 3.5 mL of purified water. The product was then flash-frozen and lyophilized to dryness to give a white fibrous material. The dried product was first dissolved in 100 mM NaOH at a concentration of 4 mg/mL and the mixture stirred for 1-2 min and then diluted to 0.5 mg/mL with buffer consisting of 50 mM Tris (pH 7.3), 50 mM KCl, and 1 mM CaCl₂. The product was then tested for sPLA2 enzyme inhibition using the fluorometric enzyme assay or for alkylation protection of hGIIA sPLA₂.

The percent loading for the HA-inhibitor conjugation reaction was determined from the molar ratio of inhibitor to HA carboxylate (HA-COOH) groups and is defined as (moles inhibitor/moles of HA-COOH) × 100. Molar ratios were obtained from two different methods (fluorescence-based or NMR-based). In the fluorescence-based method, molar ratios were calculated by obtaining the fluorescence of a known milligram amount of the HA-inhibitor conjugate and comparing it to a standard curve of fluorescence versus the known nanomole amount of free inhibitor (the fluorescence of the conjugated inhibitor and that of the free inhibitor were assumed to be identical) (see Table S1 of the Supporting Information). The fluorescence value of the HA-inhibitor conjugate was converted to nanomoles of inhibitor per milligram of HA and then to nanomoles of inhibitor to nanomoles of HA disaccharide unit. This ratio was then converted to nanomoles of inhibitor to nanomoles of HA-COOH. Fluorescence measurements were taken on a Victor3V microtiter plate spectrophotometer (Perkin-Elmer) with a 355 nm excitation filter and a 460 nm emission filter. In the NMRbased method, the percent loading of inhibitor onto total available HA-COOH groups was obtained by comparing the integrated methyl peak of the N-acetyl group of HA to the integrated methylene peak of the inhibitor N-benzyl group. For ¹H NMR experiments, dried HA-inhibitor conjugates were suspended in D_2O followed by addition of 5–10 μ L of NaOD to solubilize the product. Typically, the dried HA-inhibitor conjugates could not be dissolved in acidic or neutral solutions and required basic conditions for solubilization.

■ RESULTS

Structural Features of GIIA sPLA₂ Selective Inhibitors. To further investigate the GIIA sPLA₂ selectivity effect observed for compound 2a, we generated analogues of compound 1 as well as similar indolizine (3a-e) and carbazole (4a-h) analogues in which the carboxylate group responsible

for the general sPLA₂ potency was replaced with other functionality (Table 1). We found that replacing the

Table 1. IC₅₀ Values of Inhibitors against Human GIIA, GV, and GX sPLA₂s^a

$$R_1$$
 O NH_2 R_1 O NH_2 R_1 O NH_2

1, 2a-c 3a-e $\frac{1}{IC_{50}}$ (nM) $\frac{1}{IC_{50}}$ $\frac{1}{IC_{5$

comp	R_1	hGIIA	hGV	hGX
1	HO Joseph	40±2	35±7	20±3
2a	Me _x xx	14±2	>1600	1500±300
2b	HO	20±1	>1600	≈1600
2c	H_2N $_{S^{F^{F^{C}}}}$	35±5	>1600	1400±150
3a	Me _{rr} r	35±2	>1600	>1600
3b	HO	20±3	>1600	>1600
3c	H_2N $_{s}$ $_{s}$ $_{s}$ $_{s}$ $_{s}$ $_{s}$ $_{s}$	20±2	>1600	>1600
3d	MeOsz ^z z ^z	200±40	>1600	>1600
3e	H ₂ N v soft ^r	25±5	≈1600	>1600
4a	Me _r r	70±20	>1600	>1600
4b	HO pr	100±15	>1600	≈1600
4c	H ₂ N	40±2	>1600	≈1600
4d	H_2N O P^{F^c}	130±15	>1600	>1600
4e	H_2N O $_{r^{p^{r^{r}}}}$	210±20	>1600	>1600
4f	H_2N O O O G	430±30	>1600	>1600
4g	Me N	140±20	>1600	>1600
4h	N√3rt	>1600	>1600	>1600

 $^{\prime\prime}IC_{50}$ values were obtained from the fluorometric assay and are reported as means of triplicate analysis with standard deviations. Values of >1600 or $\approx \! 1600$ nM are reported for compounds with IC_{50} values of $\geq \! 1600$ nM.

carboxylate with a hydroxy (2b and 3b), amino (2c, 3c, and 4c), or amide (3e) group did not alter hGIIA sPLA₂ inhibition potency but led to a ≥70-fold increase in the IC₅₀ values against hGV and hGX sPLA₂s (Table 1). Slightly larger groups such as methyl ether (3d) or dimethylamino (4g) substituents resulted in 7−10-fold decreases in hGIIA sPLA₂ inhibition potency, and even larger groups such as a piperidine (4h) completely abolished the inhibitory effect. The length of the substituent also influenced hGIIA sPLA₂ inhibition potency. Carbazole inhibitors 4c−f, in which the chain length was increased in increments of ethylene glycol units, experienced a corresponding decrease in hGIIA sPLA₂ inhibition potency, but not selectivity (Table 1). Also, the type of scaffold (benzo-fused indole, indolizine, or carbazole) had no influence on the hGIIA sPLA₂ inhibition potency or selectivity.

In addition to replacing the carboxylate moiety with other functional groups, we also investigated the effects of lengthening the distance between the carboxylate group and inhibitor scaffold. Increasing the distance from one methylene (compound 1) to three methylene groups (compound 4b) had a minimal effect on hGIIA sPLA₂ inhibition potency but severely diminished inhibition potency on hGV and hGX sPLA₂s (Table 1).

Benzo-fused indole compounds 1, 2a, and 2c were selected for further hGIIA $sPLA_2$ inhibition studies in radiometric and pH-stat enzyme assays. Results from these studies are listed in Table 2 along with results from the fluorometric assay. IC_{50}

Table 2. Inhibition Potencies of Benzo-Fused Indole Inhibitors in Different sPLA₂ Activity Assays

	IC ₅₀ (nM) against hGIIA sPLA ₂				
compd	fluorometric assay ^a	radiometric assay ^b	pH-stat assay ^c		
1	40 ± 2	2 ± 1	<14		
2a	14 ± 2	95 ± 10	25		
2c	35 ± 5	520 ± 90	95		

 $^a\mathrm{IC}_{50}$ values reported from Table 1. $^b\mathrm{IC}_{50}$ values reported as the mean of duplicate analysis with standard deviations. $^c\mathrm{IC}_{50}$ values reported from singlet analysis.

values for compounds 1 and 2a were all ≤100 nM among the three assays (Table 2). Some variation in IC₅₀ values was observed for 2c, where the IC₅₀ was 35 nM in the fluorometric assay, 520 nM in the radiometric assay, and 95 nM in the pHstat assay. We have shown previously with this class of inhibitors that replacing one of the oxalamide hydrogens with a methyl group results in a dramatic decrease in the level of inhibition of GIIA, GV, and GX sPLA2 activity. 10 This is most likely because addition of the methyl group to the oxalamide would introduce steric clash and disrupt a key hydrogen bond interaction that is depicted in the crystal structure of Me-Indoxam bound in the active site of hGX sPLA₂ (Figure 1B). We thus synthesized N-methyl oxalamide analogues of compounds 1, 2a, and 2c (termed 1-Nme, 2a-Nme, and 2c-Nme, respectively) to test for the importance of the oxalamide group with respect to inhibition potency. Compounds 1-Nme, 2a-Nme, and 2c-Nme showed no observable inhibition potency in the fluorometric assay (Table S2 of the Supporting Information). We also tested 2a-Nme in the radiometric and pH-stat assays and observed <15% inhibition at concentrations that gave >90% inhibition for 2a (Table S2 of the Supporting Information).


Investigation of Active Site Binding. Attempts to obtain a crystal structure of 2a or 2c bound to hGIIA sPLA2 were unsuccessful, so we turned to an enzyme alkylation assay to probe hGIIA sPLA2 binding. In this assay, hGIIA sPLA2 is incubated in the presence of an alkylating agent that irreversibly alkylates the active site histidine to shut down enzyme activity. However, in the presence of an active site binding ligand, the rate of enzyme alkylation decreases depending on the ligand type and/or concentration. We can therefore use this assay to probe whether GIIA sPLA2 selective compounds bind the hGIIA sPLA₂ active site, as well as determine equilibrium dissociation constants of an inhibitor from the active site. This assay has been used previously to study ligand active site binders of hGIIA and other sPLA2s. $^{20-22}$ We tested compounds 1, 2a, and 2c for their ability to protect against active site alkylation in the presence or absence of calcium or a membrane interface. Because all three compounds inhibited hydrolysis of DMPM vesicles at nanomolar concentrations in the pH-stat assay (Table 2), we selected the nonhydrolyzable ether analogue of DMPM, known as DTPM, to act as the membrane

surface in the alkylation protection studies. We also chose DTPM because it has been previously shown that $\rm hGIIA~sPLA_2$ binds tightly to the surface of DTPM vesicles but has a very low binding affinity for DTPM monomers in the enzyme active site.²⁰

The effects of DTPM vesicles on hGIIA sPLA2 inactivation half-times in the presence or absence of calcium were tested under our assay conditions. We found the half-times for hGIIA sPLA₂ inactivation in the absence of CaCl₂ (100 μM EGTA) and the absence or presence of DTPM vesicles to be 11 \pm 1 and 12 ± 2 min, respectively (average of at least three experiments). Similarly, we found the half-times for hGIIA sPLA2 inactivation in the presence of 200 µM CaCl2 and the absence or presence of DTPM vesicles to be 20 \pm 3 and 24 \pm 4 min, respectively (average of at least six experiments). The similar inactivation rates of enzyme activity in the presence or absence of DTPM indicate that very little DTPM monomer occupies the hGIIA sPLA2 active site to protect against alkylation. Also, under our assay conditions of 200 μ M DTPM and 250 nM hGIIA sPLA2, the enzyme is expected to be >90% bound to the membrane surface. 20 Thus, we can test inhibitors using a scenario in which the hGIIA sPLA2 enzyme is essentially all bound to a membrane surface but the active site is mostly occupied by solvent molecules.

Representative results from the alkylation protection assay are shown in Figure 2A with semilogarithmic plots of enzyme inactivation in the presence of calcium, DTPM, and five different ${\bf 2a}$ concentrations. As depicted in Figure 2A, increasing the inhibitor concentration causes a corresponding decrease in the rate of enzyme alkylation that ranges from mostly complete protection at $5~\mu{\rm M}$ ${\bf 2a}$ to almost no protection at $0.1~\mu{\rm M}$ ${\bf 2a}$. A Scrutton and Utter plot was generated from the half-times of inactivation in the presence and absence of inhibitor and then used to calculate the $K_{\rm d}$ value of ${\bf 2a}$ for hGIIA sPLA2 in the presence of calcium and membrane (Figure 2B and Table 3). Similar plots were obtained for ${\bf 1}$, ${\bf 2a}$, and ${\bf 2c}$ in the presence and absence of calcium and/or membrane (Figures S1–S5 of the Supporting Information). The $K_{\rm d}$ values obtained from these plots are reported in Table 3.

As reported in Table 3, compound 1 showed tight binding to hGIIA sPLA₂ in the presence of 200 µM CaCl₂ and in the presence or absence of DTPM. Unfortunately, limitations in the alkylation protection assay prevented us from using lower enzyme concentrations to obtain more accurate values of K_d for compound 1. In the presence of 200 μ M CaCl₂ and 200 μ M DTPM, we observed nearly stoichiometric binding of 1 to the hGIIA sPLA₂ active site, whereas in the absence of 200 μ M DTPM, a 10-fold higher concentration of compound 1 over enzyme was required to fully protect against alkylation (Figures S4 and S5 of the Supporting Information). Compound 1 showed no measurable affinity to the hGIIA sPLA, active site in the absence of calcium (Table 3 and Figure S6 of the Supporting Information). For compounds 2a and 2c, protection against alkylation was observed only in the presence of DTPM, and the K_d values for 2a and 2c were all \leq 400 nM (Table 3 and Figure S7 of the Supporting Information). Interestingly, binding of 2a and 2c in the presence of DTPM membranes was Ca2+-independent. This lack of hGIIA sPLA2 binding in the absence of membranes was further supported by isothermal titration calorimetry involving compound 4c. No heat of binding was detected when 4c was added to hGIIA sPLA₂ in the absence of a membrane (Figure S8 of the Supporting Information). However, titration of a carbazole






Figure 2. Representative example of $K_{\rm d}$ determination using the alkylation protection assay. (A) Semilogarithmic plots for the kinetics of hGIIA sPLA₂ inactivation by phenacyl bromide in the presence of 200 μ M CaCl₂, 200 μ M DTPM, and different concentrations of compound 2a. The negative control denotes conditions under which phenacyl bromide is not included in the assay mixture. Each plot represents the mean of quadruplicate analysis with error bars representing the standard deviation. (B) Scrutton and Utter plots for each of the four individual experiments. The $K_{\rm d}$ value was determined from the x-intercept $\left(-1/K_{\rm d}\right)$ of the linear equation fitting each plot.

Table 3. $K_{\rm d}$ Values Determined via the Alkylation Protection Assay^a

	$K_{\rm d}$ (nM)				
compd	0 μM DTPM, 200 μM CaCl ₂	0 μM DTPM, 100 μM EGTA	200 μM DTPM, 200 μM CaCl ₂	200 μM DTPM, 100 μM EGTA	
1	≈250	>2500	<125	>2500	
2a	>5000	>5000	400 ± 50	350 ± 40	
2c	>5000	>5000	330 ± 20	280 ± 30	

^aEach $K_{\rm d}$ value is reported as the mean of at least quadruplicate analysis with standard deviations. Values of >5000 or >2500 nM were reported in cases of no measurable binding.

analogue of compound 1 (4i) into a solution of hGIIA sPLA₂ without a membrane resulted in a binding curve that could be fit to the standard single-site biding model with a $K_{\rm d}$ of \approx 270 nM (Figure S8 of the Supporting Information).

We also tested the *N*-methyl control compounds 1-Nme, 2a-Nme, and 2c-Nme in the alkylation protection assay and mostly observed no measurable binding affinity for the hGIIA sPLA₂ enzyme (Figure S9 of the Supporting Information). The one exception was 2c-Nme, which showed an 18-fold increase in K_d when tested in the presence of 200 μ M DTPM without calcium (Figure S9 of the Supporting Information).

Development of Hyaluronic Acid—Inhibitor Conjugates. Our approach to developing an HA—inhibitor conjugate

Scheme 1^a

"Reagents and conditions: (a) EDC, HOBt in a 1:1 THF/0.1 M MES mixture (pH 5.1), 2 h at room temperature.




Figure 3. Inhibition of hGIIA sPLA₂ activity by 4d or 4d-Nme conjugated to hyaluronic acid (HA) (HA-4d or HA-4d-Nme, respectively) in the fluorometric enzyme assay. Also, HA mixed with 4d but no coupling reagents (HA+4d), HA treated with linker only (HA-NH₂CH₂OCH₂OH₂OH), and free HA were also tested for the inhibition of hGIIA sPLA₂. Each plot is the mean of triplicate experiments with error bars representing the standard deviation.

was to covalently attach a GIIA sPLA2 selective inhibitor with a free amine to the carboxylate group of HA using peptide coupling chemistry. Methods for conjugating free aminecontaining small molecules to HA have been reported previously.^{23,24} For HA conjugation, we selected compound 4d because our docking studies suggested that the length of the linker between the free amine and inhibitor scaffold of 4d was sufficient for the inhibitor to attach to HA and extend into the enzyme active site (Figure S10 of the Supporting Information). Also, we chose the carbazole scaffold because its highly fluorescent properties provide an analytical advantage over those of the benzo-fused indole and indolizine scaffolds. The HA conjugate, HA-4d, was prepared from peptide coupling conditions using EDC/HOBt in a 1:1 THF/0.1 M MES mixture (pH 5.1) (Scheme 1). The percent loading of 4d onto HA was calculated from the molar ratio of inhibitor to HA-COOH using two different methods [fluorescence-based and NMR-based (see Materials and Methods)]. Both methods gave similar values of 9% loading (fluorescence-based) and 8% loading (NMR-based) of inhibitor onto the total possible HA-COOH groups (Table S1 of the Supporting Information). For these initial studies, we selected 20 kDa HA because of its lower viscosity and ease of handling compared to those of highermolecular mass HA preparations.

HA-4d was tested for in vitro potency against hGIIA sPLA₂ (Figure 3). We observed that HA-4d displayed significant inhibition potency with an IC₅₀ of 7 ng/ μ L HA-4d (Figure 3). At 8% loading, this corresponds to an IC₅₀ of 1.5 μ M conjugated 4d. As controls, we tested untreated HA, HA conjugated with linker only (HA-NH2CH2CH2OCH2CH2OH), or HA mixed with 4d but no coupling reagents and then purified from the reaction mixture (HA+4d). We observed little to no inhibition from these control mixtures (Figure 3). As another control, we prepared HA conjugated with the *N*-methyl control of 4d (4d-Nme). Like all of our other N-methyl compounds, 4d-Nme is devoid of inhibition potency against hGIIA, hGV, and hGX sPLA2s (IC₅₀ values of >3300 nM for all three enzymes). We expected the HA-4d-Nme conjugate to poorly inhibit hGIIA sPLA₂ activity, but instead, we found that it inhibited hGIIA sPLA2 activity with an IC₅₀ of 33 ng/ μ L, which corresponds to 5.6 μ M conjugated 4d-Nme (Figure 3). We also tested HA-4d and the other controls for inhibition of hGV and hGX sPLA2s (Figure S11 of the Supporting Information). We observed that HA-4d inhibited hGV activity with an IC₅₀ of 33 ng/µL and showed \approx 20% inhibition against hGX activity at 33 ng/ μ L (Figure S11 of the Supporting Information). HA-4d-Nme inhibited hGV and hGX activity with nearly the same potency as HA-4d (Figure S11 of the Supporting Information).

To investigate whether ${\rm HA-4d}$ exerts its inhibitory effect by binding the hGIIA sPLA2 active site, we tested this conjugate in the alkylation protection assay. At concentrations of 100 ng/ μ L HA-4d (14.2 μ M conjugated inhibitor), we did not observe any measurable protection against active site alkylation in the presence or absence of a membrane (Figure S12 of the Supporting Information). In the presence of a membrane, the free inhibitor 4d showed nearly complete protection against alkylation at a concentration of 4 μ M (Figure S12 of the Supporting Information).

DISCUSSION

The inhibition data in Table 1 show that a number of different functional groups can replace the carboxylate of compound 1 without altering the inhibition potency against hGIIA sPLA2. Perhaps the most surprising observation is that a complete charge reversal from carboxylate to amine (2c, 3c, and 4c) has no impact on hGIIA sPLA2 inhibition potency. However, there appears to be a limit to the length and size of the group that replaces the carboxylate. We found that large increases in chain length in compounds 4c-f resulted in a corresponding decrease in inhibition potency (Table 1). Increasing the chain length probably interferes with inhibitor-membrane partitioning (see below) and/or the ability of the inhibitor to access the active site because of the increasing floppiness afforded by the ethylene glycol chain. Also, going from free amine in compound 4c to a larger piperidine group in 4h completely abrogated inhibition potency on hGIIA sPLA₂ (Table 1). This size limitation suggests that this portion of the inhibitor is not completely solvent-exposed and is likely contacting a region of the hGIIA sPLA₂ enzyme. Another important result was the lack of hGIIA sPLA₂ inhibition potency displayed by the Nmethyl amide compounds (1-Nme, 2a-Nme, and 2c-Nme) (Table S2 of the Supporting Information). This suggests that the oxalamide hydrogens make important contributions to hGIIA sPLA2 inhibition potency. Interestingly, this effect is identical for both the carboxylate inhibitor (1) and the hGIIA sPLA₂ selective inhibitors (2a and 2c), suggesting that the oxalamide-GIIA sPLA2 interactions are similar for these compounds.

It remains perplexing that the carboxylate side chain is not required for tight binding of these compounds to hGIIA sPLA₂ given that the carboxylate directly coordinates to the active site Ca²⁺ of sPLA₂s in general, including hGIIA.²⁵ We therefore considered the possibility that the inhibition of hGIIA sPLA2 is due to some sort of artifact in the fluorometric assay involving pyrPG. This seemed unlikely given that other sPLA2s are not inhibited by these compounds lacking the carboxylate side chain. We tested the inhibition potency of compounds 1, 2a, and 2c in a radiometric assay and a pH-stat assay (Table 2) and observed that potent inhibition of hGIIA sPLA2 persisted in these assays. All three compounds inhibited hGIIA sPLA2 activity at nanomolar concentrations, strongly suggesting that they bind tightly and directly to hGIIA sPLA2 and do not result in false-positive inhibition in the fluorometric assay. Interestingly, we observed a more dramatic variation in IC50 values for GIIA sPLA₂ inhibitors 2a and 2c compared to compound 1 in these three different assays, suggesting that the GIIA sPLA₂ inhibitors are more sensitive to their membrane environment than carboxylate inhibitors. The membrane environment is known to have important effects on the inhibition potency of sPLA₂ inhibitors. This is because the inhibition of sPLA₂s has additional complexity in that the degree of inhibition depends

on the concentration of the inhibitor in the membrane interface in relationship to the interfacial equilibrium dissociation constant (enzyme-inhibitor complex in the membrane giving free enzyme and free inhibitor both in the membrane). 26 The concentration of inhibitor in the membrane depends on the concentration of membrane in the assay and the equilibrium constant for partitioning of inhibitor between aqueous and membrane phases. Furthermore, favorable interactions between inhibitor and membrane components would tend to pull the inhibitor off of the enzyme, whereas unfavorable membraneinhibitor interactions would tend to promote enzyme-inhibitor binding. Thus, the degree of inhibition of sPLA2s depends also on the structure of the lipids that make up the membrane interface.²⁷ All of these factors contribute in a complex way to the extent of sPLA2 inhibition as the concentration and structure of the membrane in the different assays change.

Given that the GIIA sPLA₂ inhibitors lack the Ca²⁺-binding carboxylate, we considered the possibility that they bind remotely to the active site and cause inhibition by some sort of allosteric effect on enzyme structure or on the way in which the enzyme sits on the membrane surface. Proper positioning of the enzyme at the membrane surface presumably allows a single phospholipid molecule to efficiently diffuse from the plane of the membrane into the catalytic site to reach the catalytic residues. 28,29 Starting first with the carboxylate inhibitors, which likely bind to the active site on the basis of several X-ray structures of related inhibitors bound to various sPLA₂s, ^{11,25} we showed that compound 1 protects the active site histidine from alkylation by phenacyl bromide in the absence and presence of a nonhydrolyzable membrane interface (vesicles of DTPM) (Table 3). This was confirmed with isothermal calorimetry studies of carboxylate inhibitor 4i showing that it binds hGIIA $sPLA_2$ in the absence of a membrane (Figure S8 of the Supporting Information). In contrast, the GIIA sPLA₂ specific inhibitors 2a and 2c provided no protection to alkylation in the absence of DTPM vesicles (no binding isotherm was detected for GIIA sPLA₂ specific inhibitor 4c by isothermal calorimetry as well) (Table 3 and Figure S8 of the Supporting Information). However, in the presence of DTPM membranes, 2a and 2c provide protection from alkylation (Table 3). Thus, inhibition by these inhibitors lacking the carboxylate is due to occupancy of the active site of hGIIA sPLA₂ on the membrane

Ca²⁺ binds to the active site of GIIA sPLA₂, yet Ca²⁺ is not required for the binding of the GIIA specific inhibitors to the active site. This argues that the inhibitor is not ligated to the active site Ca²⁺, which in turn suggests that water ligates directly to Ca²⁺ in the enzyme-inhibitor complex. In the absence of inhibitors, the X-ray structures of several sPLA2s show two water molecules directly bound to Ca²⁺ with the remaining ligands coming from the protein. Both waters are displaced when phospholipid analogues and Ca2+-requiring indole sPLA2 inhibitors bind to the active site. If a water remains bound to Ca2+ in the GIIA sPLA2-inhibitor complex, the inhibitor is likely to be pushed away from the Ca²⁺ site toward the membrane. Thus, while the inhibitor protects the active site histidine from the alkylating agent, it may not sit as deeply in the active site slot as inhibitors that do coordinate to Ca²⁺. In this model, more of the GIIA sPLA₂ selective inhibitor sits in the membrane where a portion of it would directly contact phospholipids in the membrane. This would explain why binding of GIIA sPLA2 selective inhibitors requires the presence of membrane phospholipids, and it would also explain

why the energetics of inhibitor binding depends on the structure of the phospholipids that make up the membranes (recall that that IC₅₀ values and inhibitor concentration required for 50% protection from alkylation depend on the structure of the phospholipid used in the assays). In the case of inhibitors that require Ca2+ for sPLA2 binding, they are pulled more deeply into the active site slot and may not interact significantly with phospholipids left in the membrane. Jain and Berg have shown that for inhibitors that fully leave the membrane to dock into the active site slot of the membranebound sPLA2, partitioning of the inhibitor into the membrane does not enhance inhibitor-enzyme binding.²¹ This is because there is essentially no local concentration advantage to confining the inhibitor and enzyme to the same smaller volume (aqueous phase vs surface of the vesicles) if the inhibitor has to fully give up its interaction energy with the membrane to bind to the enzyme's active site. In other words, the favorable energy of binding of the inhibitor with the membrane that favors partitioning of the inhibitor from the aqueous phase to the membrane has to be given up when the inhibitor leaves the membrane to bind to the enzyme's active site. On the other hand, if a portion of the inhibitor remains in the membrane when it is docked into the active site (inhibitor is not fully extracted from the membrane), then binding of the inhibitor to the membrane may enhance enzyme-inhibitor binding. We cannot rule out the possibility that binding of the enzyme to the vesicles leads to a conformational change in the active site that is required for binding of inhibitors that lack the carboxylate but not those that contain the carboxylate; however, this seems unlikely.

Because the carboxylate is not required for high-affinity binding of these compounds to GIIA sPLA2, we thought it would be possible for GIIA sPLA2 inhibitors, bound through a linker at the 4-position of the indole scaffold, to act as potent GIIA sPLA₂ inhibitors. Thus, we explored GIIA sPLA₂ inhibitors as conjugates with HA. As stated in the introductory section, these conjugates may be useful therapeutics for the treatment of joint disorders. In comparison to that for free 4d, the IC₅₀ for HA-4d was 10-fold less potent against hGIIA sPLA₂ (1500 nM for conjugated HA-4d vs 130 nM for free 4d). However, HA-4d demonstrated much higher GIIA sPLA₂ inhibition potency than free HA, HA-NH₂CH₂CH₂OCH₂CH₂OH, and HA+4d controls (Figure 3). The fact that both HA and HA-NH2CH2CH2OCH2CH2OH failed to inhibit hGIIA sPLA2 activity rules out any possible nonspecific inhibitory effects from HA, the linker, or the conditions or reagents associated with the synthesis or purification of these conjugates. The weak inhibition observed for HA+4d is likely due to trace 4d that remains after purification. We also observed that the N-methyl control HA-4d-Nme was 4-fold less potent than HA-4d against hGIIA sPLA2 activity. This result indicates that some of the inhibitory effect of HA-4d may be nonspecific.

To gage hGIIA sPLA₂ inhibition selectivity, we tested the inhibition potency of **HA**–4**d** against hGV and hGX sPLA₂. The inhibition potency of **HA**–4**d** against hGV sPLA₂ was 5-fold lower than the inhibition potency against hGIIA. Compared to free 4**d** where the difference in IC₅₀ values for hGIIA and hGV sPLA₂ is >12-fold, conjugating the compound to HA lowers the selectivity of the GIIA sPLA₂ inhibitor. In addition, levels of inhibition of hGV sPLA₂ activity by **HA**–4**d**-**Nme** approached the levels of inhibition observed for **HA**–4**d** (Figure S11 of the Supporting Information). Because free 4**d**

and 4d-Nme display no inhibition potency against hGV, this suggests that hGV inhibition by the conjugated forms of these inhibitors (HA–4d and HA–4d-Nme) probably occurs through a nonspecific mechanism. Interestingly, the two heparin-binding sPLA₂s, GIIA and GV, show inhibition by HA–4d and HA–4d-Nme (Figure 3 and Figure S11 of the Supporting Information). It is possible that the affinity of hGIIA and hGV sPLA₂s for polyanionic surfaces, such as HA, may contribute to the inhibition. This was not the case for hGX sPLA₂, a poor binder of heparin, which was essentially unaffected by HA–4d or HA–4d-Nme (Figure S11 of the Supporting Information). This result rules out HA–4d inhibition through general membrane disruption or some other general mechanism.

To investigate whether HA-4d was able to bind the enzyme active site, we tested HA-4d in the alkylation protection assay at 100 ng/ μ L. This concentration was 3-fold higher than the concentration of HA-4d that inhibited 90% of hGIIA sPLA2 activity in the fluorescence-based assay. Results from the alkylation protection assay show that HA-4d has no measurable affinity for the active site of hGIIA sPLA2 in the presence or absence of DTPM (Figure S12 of the Supporting Information). It appears that linking 4d to HA prevents active site binding because free 4d is able to protect against alkylation (Figure S12 of the Supporting Information). These data suggest that the hGIIA sPLA2 inhibition observed from HA-4d is probably not occurring through binding the active site. Thus, while HA-4d shows inhibition of hGIIA sPLA2 activity, the decreased inhibition potency and selectivity compared to those of free 4d make it a poor candidate for further study in arthritis disease models. To circumvent these problems, HA and the inhibitor as two separate molecules or an HA-inhibitor conjugate containing a hydrolyzable linker could be developed for injection into the synovial space of the arthritic joint.

In summary, we explored the mode of inhibition of an important class of sPLA2 inhibitors that are selective for GIIA sPLA₂. 10 Previously, it was shown that removal of the carboxylate moiety from compound 1 significantly decreased the inhibition potency against hGV and hGX sPLA2s, but not against hGIIA. We found that the carboxylate moiety could be replaced with a number of different functional groups that are similar in size to the carboxylate without affecting hGIIA sPLA₂ inhibition potency and selectivity. Using inhibition data and an alkylation protection assay, we provide evidence that hGIIA sPLA₂ selective inhibitors are able to bind the hGIIA enzyme active site in an orientation similar to that of carboxylatecontaining compounds, and that this binding does not require Ca²⁺. We also conjugated the hGIIA sPLA₂ selective inhibitor 4d to HA (HA-4d) and observed that HA-4d is able to inhibit hGIIA sPLA2 activity but not through active site binding. These results are part of a growing initiative for the design and development of inhibitors that selectively target proinflammatory sPLA₂s.

ASSOCIATED CONTENT

S Supporting Information

Semilogarithmic inactivation plots and Scrutton and Utter plots used to compute K_d values in Table 3 (Figures S1–S5), semilogarithmic inactivation plots of compound 1 in the absence of calcium (Figure S6), semilogarithmic inactivation plots of compounds 2a and 2c in the absence of DTPM (Figure S7), ITC binding curves for 4c and 4i (Figure S8) and ITC experimental procedure, semilogarithmic inactivation plots of

N-methyl compounds (Figure S9), molecular modeling studies of HA–4d (Figure S10), inhibition of hGV and hGX sPLA₂ activity by HA–4d (Figure S11), semilogartihmic inactivation plots of hGIIA sPLA₂ activity in the presence of HA–4d, HA–4d-Nme, or 4d (Figure S12), percent loading determination of HA–4d and HA–4d-Nme (Table S1), inhibition data of N-methyl oxalamide control inhibitors (Table S2), and synthetic schemes and details of synthetic methods for all compounds and pyrPG, including NMR and MS data. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*Telephone: (206) 543-7142. Fax: (206) 685-8665. E-mail: gelb@chem.washington.edu.

Funding

This work was supported by a National Institutes of Health Molecular Biophysics Training Grant (R.C.O.) and a Merit Award from the National Institutes of Health (M.H.G.) (R37HL036235).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Prem Das (Synostics Inc.) for general discussions about HA conjugation, Tom Hinds (Beavo lab) for help with ITC experiments, and members of the Gelb lab for helpful discussions about this research.

ABBREVIATIONS

DMPM, 1,2-dimyristoyl-sn-glycero-3-phosphomethanol; DTPM, 1,2-ditetradecyl-sn-glycero-3-phosphomethanol; GIIA sPLA₂, group IIA secreted phospholipase A₂ (likewise for other group names); HA, hyaluronic acid; hGIIA sPLA₂, human group IIA secreted phospholipase A₂ (likewise for other group names); pyrPG, 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol.

REFERENCES

- (1) Lambeau, G., and Gelb, M. H. (2008) Biochemistry and physiology of mammalian secreted phospholipases A2. *Annu. Rev. Biochem.* 77, 495–520.
- (2) Valentin, E., and Lambeau, G. (2000) Increasing molecular diversity of secreted phospholipases A_2 and their receptors and binding proteins. *Biochim. Biophys. Acta* 1488, 59–70.
- (3) Dennis, E. A., Cao, J., Hsu, Y. H., Magrioti, V., and Kokotos, G. (2011) Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. *Chem. Rev.* 111, 6130–6185.
- (4) Reid, R. C. (2005) Inhibitors of secretory phospholipase A2 group IIA. Curr. Med. Chem. 12, 3011–3026.
- (5) Magrioti, V., and Kokotos, G. (2010) Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. *Expert Opin. Ther. Pat.* 20, 1–18.
- (6) Pruzanski, W., Vadas, P., Stefanski, E., and Urowitz, M. B. (1985) Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme. *J. Rheumatol.* 12, 211–216.
- (7) Seilhamer, J. J., Pruzanski, W., Vadas, P., Plant, S., Miller, J. A., Kloss, J., and Johnson, L. K. (1989) Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. *J. Biol. Chem.* 264, 5335–5338.
- (8) Boilard, E., Lai, Y., Larabee, K., Balestrieri, B., Ghomashchi, F., Fujioka, D., Gobezie, R., Coblyn, J. S., Weinblatt, M. E., Massarotti, E.

M., Thornhill, T. S., Divangahi, M., Remold, H., Lambeau, G., Gelb, M. H., Arm, J. P., and Lee, D. M. (2010) A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. *EMBO Mol. Med.* 2, 172–187.

- (9) Bradley, J. D., Dmitrienko, A. A., Kivitz, A. J., Gluck, O. S., Weaver, A. L., Wiesenhutter, C., Myers, S. L., and Sides, G. D. (2005) A radomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. *J. Rheumatol.* 32, 417–423.
- (10) Oslund, R. C., Cermak, N., and Gelb, M. H. (2008) Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. *J. Med. Chem.* 51, 4708–4714.
- (11) Smart, B. P., Pan, Y. H., Weeks, A. K., Bollinger, J. G., Bahnson, B. J., and Gelb, M. H. (2004) Inhibition of the complete set of mammalian secreted phospholipases A2 by indole analogues a structure-guided study. *Bioorg. Med. Chem.* 12, 1737–1749.
- (12) George, E. (1998) Intra-articular hyaluronan treatment for osteoarthritis. *Ann. Rheum. Dis.* 57, 637–640.
- (13) Neustadt, D., Caldwell, J., Bell, M., Wade, J., and Gimbel, J. (2005) Clinical effects of intraarticular injection of high molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee: A randomized, controlled, multicenter trial. *J. Rheumatol.* 32, 1928–1936.
- (14) Koduri, R. S., Baker, S. F., Snitko, Y., Han, S. K., Cho, W., Wilton, D. C., and Gelb, M. H. (1998) Action of human group IIa secreted phospholipase A2 on cell membranes. Vesicle but not heparinoid binding determines rate of fatty acid release by exogenously added enzyme. *J. Biol. Chem.* 273, 32142–32153.
- (15) Singer, A. G., Ghomashchi, F., Le Calvez, C., Bollinger, J., Bezzine, S., Rouault, M., Sadilek, M., Nguyen, E., Lazdunski, M., Lambeau, G., and Gelb, M. H. (2002) Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J. Biol. Chem. 277, 48535–48549.
- (16) Jain, M. K., Rogers, J., Jahagirdar, D. V., Marecek, J. F., and Ramirez, F. (1986) Kinetics of interfacial catalysis by phospholipase A2 in intravesicle scooting mode, and heterofusion of anionic and zwitterionic vesicles. *Biochim. Biophys. Acta* 860, 435–447.
- (17) Smart, B. P., Oslund, R. C., Walsh, L. A., and Gelb, M. H. (2006) The first potent inhibitor of mammalian group X secreted phospholipase A2: Elucidation of sites for enhanced binding. *J. Med. Chem.* 49, 2858–2860.
- (18) Oslund, R. C., Cermak, N., Verlinde, C. L., and Gelb, M. H. (2008) Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. *Bioorg. Med. Chem. Lett.* 18, 5415–5419.
- (19) Jain, M. K., and Gelb, M. H. (1991) Phospholipase A2-catalyzed hydrolysis of vesicles: Uses of interfacial catalysis in the scooting mode. *Methods Enzymol.* 197, 112–125.
- (20) Bayburt, T., Yu, B. Z., Lin, H. K., Browning, J., Jain, M. K., and Gelb, M. H. (1993) Human nonpancreatic secreted phospholipase A2: Interfacial parameters, substrate specificities, and competitive inhibitors. *Biochemistry* 32, 573–582.
- (21) Jain, M. K., Yu, B. Z., Rogers, J., Ranadive, G. N., and Berg, O. G. (1991) Interfacial catalysis by phospholipase A2: Dissociation constants for calcium, substrate, products, and competitive inhibitors. *Biochemistry* 30, 7306–7317.
- (22) Ghomashchi, F., Yu, B. Z., Mihelich, E. D., Jain, M. K., and Gelb, M. H. (1991) Kinetic characterization of phospholipase A2 modified by manoalogue. *Biochemistry* 30, 9559–9569.
- (23) Homma, A., Sato, H., Okamachi, A., Emura, T., Ishizawa, T., Kato, T., Matsuura, T., Sato, S., Tamura, T., Higuchi, Y., Watanabe, T., Kitamura, H., Asanuma, K., Yamazaki, T., Ikemi, M., Kitagawa, H., Morikawa, T., Ikeya, H., Maeda, K., Takahashi, K., Nohmi, K., Izutani, N., Kanda, M., and Suzuki, R. (2009) Novel hyaluronic acidmethotrexate conjugates for osteoarthritis treatment. *Bioorg. Med. Chem.* 17, 4647–4656.
- (24) Kurisawa, M., Chung, J. E., Yang, Y. Y., Gao, S. J., and Uyama, H. (2005) Injectable biodegradable hydrogels composed of hyaluronic acid-tyramine conjugates for drug delivery and tissue engineering. *Chem. Commun.*, 4312–4314.

Biochemistry

(25) Kitadokoro, K., Hagishita, S., Sato, T., Ohtani, M., and Miki, K. (1998) Crystal structure of human secretory phospholipase A2-IIA complex with the potent indolizine inhibitor 120-1032. *J. Biochem.* 123, 619–623

- (26) Jain, M. K., Yuan, W., and Gelb, M. H. (1989) Competitive inhibition of phospholipase A2 in vesicles. *Biochemistry* 28, 4135–4139.
- (27) Lin, H. K., and Gelb, M. H. (1993) Competitive inhibition of interfacial catalysis by phospholipase A2: Differential interaction of inhibitors with vesicle interface as controlling factor of inhibitor potency. *J. Am. Chem. Soc.* 115, 3932–3942.
- (28) Scott, D. L., White, S. P., Otwinowski, Z., Yuan, W., Gelb, M. H., and Sigler, P. B. (1990) Interfacial catalysis: The mechanism of phospholipase A2. *Science 250*, 1541–1546.
- (29) Ramirez, F., and Jain, M. K. (1991) Phospholipase A2 at the bilayer interface. *Proteins* 9, 229–239.